{"schema_version":"1.0","type":"article","title":"氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.md","lang":"zh-Hant","date":"2026-05-25","publish_at":"2026-05-25T10:30:00+08:00","updated_at":"2026-05-25","category":"商業分析系列","topic":"臨床與 CMC","tags":["氣喘","吸入三合一","免疫靶點","生物製劑","呼吸道疾病"],"summary":"氣喘治療正在從吸入三合一與症狀控制，走向上游免疫靶點、生物製劑與更精準的病人分型。","key_points":[],"facts":[],"sections":["吸入治療仍是地基，但三合一正在往前線移動","表格 1：代表性氣喘藥物與臨床定位","生物製劑讓氣喘進入精準治療時代","圖解：第二型發炎與氣喘新藥靶點","下一場競賽：不是只打單一靶點，而是往上游與多靶點走","表格 2：下一代氣喘研發靶點與產業意義","市場為什麼願意押注氣喘？","產業圖：全球氣喘新藥邏輯如何對應台灣公司","台灣可以看什麼？","結語","參考資料 / 延伸閱讀"],"references":[],"images":[{"alt":"Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-01.webp"},{"alt":"Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-02.webp"},{"alt":"Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-03.jpg"},{"alt":"Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-04.jpg"},{"alt":"Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-05.jpg"}],"cover_image":"https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-25）。氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!。https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-25-asthma-new-drug-immune-targets-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}